Chemed

Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The Roto-Rooter segment includes plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers. The company was founded in 1970 and is headquartered in Cincinnati, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Chemed exceeds earnings expectations, focuses on strategic growth initiatives

Chemed's strong financial performance in 2022 was supported by targeted hiring and retention efforts.
Both VITAS and Roto-Rooter are focusing on improving staffing and revenue growth.
Chemed's strategic initiatives position the company well for future growth and operational efficiency.
The company's emphasis on culture and strategic approaches enhances valuation in the M&A market.

Chemed reports strong Q1 performance, optimistic about growth trajectory

Chemed's Q1 2023 earnings call highlighted a positive performance trajectory post-pandemic, with a focus on VITAS' growth and operational strategies. The company addressed challenges related to Medicare reimbursement rates and emphasized opportunities for further expansion and staff satisfaction.

Chemed's VITAS shines, Roto-Rooter adapts to consumer challenges

Chemed's Q2 2023 earnings call highlighted VITAS' strong performance and operational improvements post-pandemic.
Roto-Rooter faced challenges in consumer spending but focused on enhancing online presence and conversion rates.
Both segments showcased resilience amidst economic headwinds, with strategic initiatives in place to drive growth and operational efficiency.
Chemed's strategic cost management and revenue generation strategies position the company for sustainable growth and margin protection.

Chemed reports strong Q3 performance, eyes growth amid economic challenges

Chemed's diversified business segments showed resilience and growth potential, with VITAS Healthcare and Roto-Rooter both demonstrating strengths and addressing challenges. The company remains cautiously optimistic about 2024, focusing on operational efficiency and market dynamics for sustained performance.

Chemed's VITAS shines in Q4 with strong growth, Roto-Rooter faces challenges

Chemed's VITAS segment excelled with strong revenue growth and operational improvements, while Roto-Rooter faced challenges in call volume.
Management's confidence in sustained growth and margin improvement presents opportunities for both VITAS and Roto-Rooter in 2024.
Strategies to address challenges and capitalize on opportunities will be crucial for Chemed's divisions to meet their forecasted targets.
Overall, Chemed's performance in Q4 2023 sets a positive tone for the company's outlook and strategic initiatives moving forward.

Chemed excels in hospice segment, Roto-Rooter faces commercial challenges

Chemed's VITAS segment outperformed, while Roto-Rooter faced challenges, prompting strategic actions to enhance commercial performance and drive growth.

Chemed's VITAS shines in Q2 2024, Roto-Rooter faces revenue challenges

Chemed's VITAS segment is driving revenue growth and margin expansion, while Roto-Rooter faces challenges in revenue decline. The company aims to capitalize on growth opportunities in the hospice services sector.

Chemed's VITAS shines amid Roto-Rooter's challenges in Q3 2024

Chemed's earnings call showcased VITAS' resilience and growth prospects, while addressing Roto-Rooter's challenges and strategic adjustments. The company remains optimistic about adjusted net income outlook for the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chemed's (CHE) robust VITAS business and strong financial stability raise investors' optimism.

Should You Keep Chemed (CHE) Stock in Your Portfolio Now?

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the second quarter ended June 30, 2024, on Wednesday, July 24, 2024, following the close of trading on the New York Stock Exchange. Chemed will host a conference call and webcast at 10 a.m., ET, on Thursday, July 25, 2024, to discuss the company's quarterly results and to provide an update on its business. Participants may access a live webcast of the conference call through th.

Chemed To Report Second-Quarter 2024 Earnings July 24, Related Conference Call To Be Held On July 25

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the Jefferies 2024 Global Healthcare Conference on Wednesday, June 5, 2024, at approximately 9:00 a.m. (ET) at the New York Marriott Marquis in New York City. The presentation will be webcast live and can be accessed, along with the presentation materials, through the Chemed website at www.chemed.com (Investor Relations). The webcast replay will be available within 24 hours of the.

Chemed Corporation to Present at the Jefferies 2024 Global Healthcare Conference

CINCINNATI--(BUSINESS WIRE)--Stockholders of Chemed Corporation (NYSE:CHE) today elected a slate of 10 directors at the Company's 2024 annual stockholders' meeting. Stockholders ratified the continuation of PricewaterhouseCoopers LLP as the Company's independent accountants for 2024. Stockholders also approved Chemed's executive compensation. In addition, stockholders voted against the stockholder proposal on ratification of termination pay. Dividend Declared Following the stockholders' meeting.

Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend

Chemed Corp. is rated as a hold due to high stock price assumptions for future revenue growth. CHE has two business lines: VITAS, which offers hospice care, and Roto-Rooter, which provides plumbing and drain cleaning services. VITAS has competitive advantages as one of the largest providers of hospice services, while Roto-Rooter faces more competition and weaker growth prospects.

Chemed: Growth Does Not Justify The Current Stock Price

Chemtrade Logistics Income Fund (OTC:CGIFF) Q1 2024 Earnings Conference Call May 16, 2024 8:30 AM ET Company Participants Rohit Bhardwaj - Chief Financial Officer Scott Rook - President and CEO Conference Call Participants Jacob Bout - CIBC Anthony Taglieri - BMO Capital Markets Gary Ho - Desjardins Capital Markets Steve Hansen - Raymond James Zachary Evershed - National Bank Financial Operator Good morning, ladies and gentlemen, and welcome to the Chemtrade Logistics Income Fund Q1 2024 Conference Call. At this time, all lines are in a listen-only mode.

Chemtrade Logistics Income Fund (CGIFF) Q1 2024 Earnings Call Transcript

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Bank of America Securities Health Care Conference 2024 on Tuesday, May 14, 2024, at 1:40 PM (PDT) at the Encore at the Wynn Las Vegas. The presentation will be webcast live and can be accessed, along with the presentation materials, through the Chemed website at www.chemed.com (Investor Relations). The webcast replay will be available within 24 hours of the live presentation and.

Chemed Corporation to Present at the Bank of America Securities Health Care Conference 2024

Encompass Health

Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Encompass Health (EHC) or Chemed (CHE). But which of these two stocks offers value investors a better bang for their buck right now?

EHC or CHE: Which Is the Better Value Stock Right Now?

Chemed's (CHE) first-quarter 2024 results reflect VITAS' impressive revenue growth and improved average revenues per patient per day.

Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View

Chemed (CHE) came out with quarterly earnings of $5.20 per share, missing the Zacks Consensus Estimate of $5.47 per share. This compares to earnings of $4.82 per share a year ago.

Chemed (CHE) Q1 Earnings Miss Estimates

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation's largest providers of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its first quarter ended March 31, 2024, versus the comparable prior-year period. Changes to Non-GAAP Metrics Chemed uses certain non-GAAP metrics such as EBITDA, adjusted EBI.

Chemed Reports First-Quarter 2024 Results

Investors are optimistic about Chemed (CHE), backed by the strong performance of the VITAS Healthcare and Roto-Rooter segments.

Here's Why You Should Retain Chemed (CHE) Stock for Now

CINCINNATI--(BUSINESS WIRE)--VITAS Healthcare Corporation, a wholly-owned subsidiary of Chemed Corporation (“Chemed”) (NYSE: CHE) announced the completion of the previously announced purchase of all hospice operations and an assisted living facility from Covenant Health and Community Services, Inc. d/b/a/ Covenant Care (“Covenant”) for an aggregate purchase price of $85 million. The transaction is structured as an asset purchase. Covenant's hospice operations span the panhandle of Florida and A.

VITAS Completes the Previously Announced Purchase of Assets of Covenant in Florida and Alabama

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the first quarter ended March 31, 2024, on Wednesday, April 24, 2024, following the close of trading on the New York Stock Exchange. Chemed will host a conference call and webcast at 10 a.m., ET, on Thursday, April 25, 2024, to discuss the company's quarterly results and to provide an update on its business. Participants may access a live webcast of the conference call through.

Chemed To Report First-Quarter 2024 Earnings April 24, Related Conference Call To Be Held On April 25

Chemed (CHE) reported earnings 30 days ago. What's next for the stock?

Chemed (CHE) Up 2.5% Since Last Earnings Report: Can It Continue?

Investors are optimistic about Chemed (CHE) on strong performance across the VITAS and Roto-Rooter segments.

Chemed (CHE) Reaches a New 52-Week High: What's Driving It?

Chemed's (CHE) VITAS segment is set to acquire the hospice assets of Covenant Care in Florida and Alabama.

Chemed's (CHE) VITAS Segment Inks New Deal With Covenant Care

CINCINNATI--(BUSINESS WIRE)--VITAS Healthcare Corporation, a wholly-owned subsidiary of Chemed Corporation (“Chemed”) (NYSE: CHE), announced it entered into an agreement on March 12, 2024 to acquire all hospice operations and an assisted living facility from Covenant Health and Community Services, Inc. d/b/a/ Covenant Care (“Covenant”) for an aggregate purchase price of $85 million. Covenant's hospice operations span the panhandle of Florida and Alabama, specifically including the Tallahassee,.

VITAS To Buy Hospice Assets of Covenant Care in Florida and Alabama

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the Oppenheimer 34th Annual Healthcare Conference on Tuesday, March 12, 2024, at approximately 12:00 p.m. (ET). The virtual presentation will be webcast live and can be accessed, along with the presentation materials, through the Chemed website at www.chemed.com (Investor Relations). The webcast replay will be available within 24 hours of the live presentation and will be ac.

Chemed Corporation to Present at the Oppenheimer 34th Annual Healthcare Conference

Chemed (CHE) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Is Chemed (CHE) a Solid Growth Stock? 3 Reasons to Think "Yes"

Chemed's (CHE) fourth-quarter 2023 performance reflects an improvement in VITAS' operational metrics.

Chemed (CHE) Q4 Earnings Surpass Estimates, Margins Expand

Chemed Corporation (CHE) Q4 2023 Earnings Call Transcript

The headline numbers for Chemed (CHE) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Chemed (CHE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Chemed (CHE) came out with quarterly earnings of $6.60 per share, beating the Zacks Consensus Estimate of $6.25 per share. This compares to earnings of $5.39 per share a year ago.

Chemed (CHE) Tops Q4 Earnings Estimates

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation's largest providers of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its fourth quarter ended December 31, 2023, versus the comparable prior-year period. Changes to Non-GAAP Metrics Chemed uses certain non-GAAP metrics such as EBITDA, adjusted.

News for Chemed Stock (CHE)